Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | BCL2 | P10415 | 8/20 | 0.48 |
| ▸ | BAK1 | Q16611 | 3/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | BID | P55957 | 1/20 | 0.43 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26682227 | 0.89 | CHEK1 (0.47) | HTR7CHEK1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL26681288 | 0.86 | OPRD1 (0.48) | HTR7BCL2BAK1BCL2L1MAPT | |
| SCHEMBL26682055 | 0.86 | HTR7 (0.60) | HTR7BCL2BAK1BCL2L1MAPT | |
| SCHEMBL26845152 | 0.86 | BCL2 (0.48) | HTR7BCL2BAK1BCL2L1MAPT | |
| SCHEMBL29792980 | 0.85 | BCL2 (0.56) | BCL2BAK1BCL2L1 | |
| SCHEMBL26681641 | 0.85 | BCL2 (0.56) | BCL2BAK1BCL2L1 | |
| SCHEMBL26681292 | 0.85 | BCL2 (0.52) | BCL2BAK1BCL2L1 | |
| SCHEMBL26680907 | 0.85 | BCL2 (0.70) | CHEK1BCL2BAK1BCL2L1 | |
| SCHEMBL24619853 | 0.85 | BCL2 (0.47) | HTR7BCL2BAK1BCL2L1MAPT | |
| SCHEMBL26845174 | 0.85 | BCL2 (0.47) | HTR7BCL2BAK1BCL2L1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | HTR7 4034/4885CHEK1 1231/4885BCL2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.